- Home
- FLC vs STXS Comparison
FLC vs STXS Comparison
Compare FLC & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | STXS |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.1M | 164.1M |
| IPO Year | 2003 | 2004 |
Fundamental Metrics
Financial Performance| Metric | FLC | STXS |
|---|---|---|
| Price | $16.48 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 14.8K | ★ 545.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.89 | $1.24 |
| 52 Week High | $18.09 | $3.59 |
Technical Indicators
Market Signals| Indicator | FLC | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 46.78 |
| Support Level | $16.26 | $1.30 |
| Resistance Level | $17.00 | $1.51 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 6.82 | 34.37 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.